• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自体和异体人原发性胆管细胞类器官细胞疗法的免疫原性

Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies.

作者信息

Petrus-Reurer Sandra, Lei Winnie, Tysoe Olivia, Mairesse Maelle, Baez-Ortega Adrian, Jones Julia, Tan Thomas, Rehakova Sylvia, Mahbubani Krishnaa T, Brodie Cara, Han Namshik, Martincorena Inigo, Betts Catherine, Vallier Ludovic, Saeb-Parsy Kourosh

机构信息

Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK.

Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK; Milner Therapeutics Institute, University of Cambridge, Cambridge CB2 0AW, UK.

出版信息

Cell Rep Med. 2025 Jul 15;6(7):102205. doi: 10.1016/j.xcrm.2025.102205. Epub 2025 Jul 7.

DOI:10.1016/j.xcrm.2025.102205
PMID:40628261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281383/
Abstract

Primary human cells cultured in long-term expandable 3D organoid format have great promise as potential regenerative cellular therapies, but their immunogenicity has not yet been fully characterized. In this study, we use in vitro co-cultures and in vivo humanized mouse experimental models to examine autologous and allogeneic immune response to human primary cholangiocyte organoids (PCOs) as treatment for bile duct disorders. Our data demonstrate that PCOs upregulate the expression of human leukocyte antigen (HLA)-I and HLA-II in inflammatory conditions. The allogeneic immune response to PCOs is driven by both HLA-I and HLA-II and is substantially ameliorated by donor-recipient HLA matching. While allogeneic cells display evolving stages of immune rejection in vivo, autologous PCOs induce a low-level immune infiltration into the graft site possibly influenced by acquired mutations in culture, cell viability, and culture matrix. Our findings have important implications for the design and clinical translation of autologous and allogeneic organoid cellular therapies.

摘要

以长期可扩增的三维类器官形式培养的原代人细胞作为潜在的再生细胞疗法具有巨大潜力,但其免疫原性尚未得到充分表征。在本研究中,我们使用体外共培养和体内人源化小鼠实验模型来研究自体和异体对人原发性胆管细胞类器官(PCO)治疗胆管疾病的免疫反应。我们的数据表明,PCO在炎症条件下会上调人白细胞抗原(HLA)-I和HLA-II的表达。对PCO的异体免疫反应由HLA-I和HLA-II共同驱动,并且通过供体-受体HLA匹配可得到显著改善。虽然异体细胞在体内显示出免疫排斥的演变阶段,但自体PCO会诱导低水平的免疫细胞浸润到移植部位,这可能受到培养过程中获得性突变、细胞活力和培养基质的影响。我们的研究结果对自体和异体类器官细胞疗法的设计和临床转化具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/834012f72f8d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/570e9155a4be/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/019c4b4f2ff3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/1cacdf40f9ba/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/ddd1c1692620/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/e4ff451ee6af/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/7d925fbf1724/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/834012f72f8d/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/570e9155a4be/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/019c4b4f2ff3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/1cacdf40f9ba/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/ddd1c1692620/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/e4ff451ee6af/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/7d925fbf1724/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8e/12281383/834012f72f8d/gr6.jpg

相似文献

1
Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies.自体和异体人原发性胆管细胞类器官细胞疗法的免疫原性
Cell Rep Med. 2025 Jul 15;6(7):102205. doi: 10.1016/j.xcrm.2025.102205. Epub 2025 Jul 7.
2
A systematic overview of chemotherapy effects in acute myeloid leukaemia.急性髓系白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
3
Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer Patients.从原发性肿瘤和患者来源的异种移植肿瘤建立的类器官模型反映了卵巢癌患者的铂敏感性。
bioRxiv. 2025 May 2:2024.06.28.601283. doi: 10.1101/2024.06.28.601283.
4
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.与一线使用环孢素和/或抗胸腺细胞或抗淋巴细胞球蛋白治疗获得性重型再生障碍性贫血相比,HLA匹配的同胞供者进行一线异基因造血干细胞移植的情况。
Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD006407. doi: 10.1002/14651858.CD006407.pub2.
5
Evaluating the immunogenicity of a mouse partial hindlimb for composite allotransplantation.评估小鼠部分后肢复合同种异体移植的免疫原性。
Front Immunol. 2025 Jun 18;16:1595319. doi: 10.3389/fimmu.2025.1595319. eCollection 2025.
6
Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage.间充质基质/干细胞促进化疗诱导损伤后的肠道上皮细胞再生。
Stem Cell Res Ther. 2024 Apr 29;15(1):125. doi: 10.1186/s13287-024-03738-9.
7
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.成人血液系统恶性肿瘤的骨髓与外周血异基因造血干细胞移植。
Cochrane Database Syst Rev. 2024 Nov 7;11(11):CD010189. doi: 10.1002/14651858.CD010189.pub3.
8
Recent Advances in Graphene Oxide-Based on Organoid Culture as Disease Model and Cell Behavior - A Systematic Literature Review.基于类器官培养的氧化石墨烯在疾病模型和细胞行为中的最新进展——系统文献综述。
Int J Nanomedicine. 2024 Jun 19;19:6201-6228. doi: 10.2147/IJN.S455940. eCollection 2024.
9
Platelet-rich therapies for musculoskeletal soft tissue injuries.用于肌肉骨骼软组织损伤的富血小板疗法。
Cochrane Database Syst Rev. 2013 Dec 23(12):CD010071. doi: 10.1002/14651858.CD010071.pub2.
10
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.造血细胞移植和细胞治疗的当前活动趋势与结果——来自CIBMTR的报告
Transplant Cell Ther. 2025 May 19. doi: 10.1016/j.jtct.2025.05.014.

本文引用的文献

1
Allorecognition Unveiled: Integrating Recent Breakthroughs Into the Current Paradigm.同种异体识别揭秘:将最新突破融入当前范式。
Transpl Int. 2024 Nov 11;37:13523. doi: 10.3389/ti.2024.13523. eCollection 2024.
2
Tregs in transplantation tolerance: role and therapeutic potential.调节性T细胞在移植耐受中的作用及治疗潜力。
Front Transplant. 2023 Aug 30;2:1217065. doi: 10.3389/frtra.2023.1217065. eCollection 2023.
3
HLA mismatch is important for 20-year graft survival in kidney transplant patients.HLA 错配对肾移植患者 20 年移植物存活率很重要。
Transpl Immunol. 2023 Oct;80:101861. doi: 10.1016/j.trim.2023.101861. Epub 2023 Jun 10.
4
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.免疫低下诱导的多能干细胞在完全免疫活性的同种异体恒河猴体内长期存活。
Nat Biotechnol. 2024 Mar;42(3):413-423. doi: 10.1038/s41587-023-01784-x. Epub 2023 May 8.
5
Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice.人类低免疫原性原发性胰岛可避免同种异体人源化小鼠发生排斥反应和自身免疫反应,并缓解糖尿病。
Sci Transl Med. 2023 Apr 12;15(691):eadg5794. doi: 10.1126/scitranslmed.adg5794.
6
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.由于激活和抑制 NK 细胞受体的配体失衡,iPSC 衍生细胞缺乏对自身 NK 细胞的免疫耐受。
Stem Cell Res Ther. 2023 Apr 11;14(1):77. doi: 10.1186/s13287-023-03308-5.
7
Interferon-γ exposure of human iPSC-derived neurons alters major histocompatibility complex I and synapsin protein expression.人诱导多能干细胞衍生神经元暴露于干扰素-γ会改变主要组织相容性复合体I和突触素蛋白的表达。
Front Psychiatry. 2022 Sep 14;13:836217. doi: 10.3389/fpsyt.2022.836217. eCollection 2022.
8
Stem cell-based therapy for human diseases.基于干细胞的人类疾病治疗方法。
Signal Transduct Target Ther. 2022 Aug 6;7(1):272. doi: 10.1038/s41392-022-01134-4.
9
Molecular profiling of stem cell-derived retinal pigment epithelial cell differentiation established for clinical translation.为临床转化而建立的干细胞来源视网膜色素上皮细胞分化的分子谱分析。
Stem Cell Reports. 2022 Jun 14;17(6):1458-1475. doi: 10.1016/j.stemcr.2022.05.005.
10
Engineering the next generation of cell-based therapeutics.工程化下一代基于细胞的治疗方法。
Nat Rev Drug Discov. 2022 Sep;21(9):655-675. doi: 10.1038/s41573-022-00476-6. Epub 2022 May 30.